Indeed, MSCs expressing high levels of CD146 display a more pronounced therapeutic effect compared to MSCs with low levels of CD146, as evident by increased survival rate in a mouse GvHD model (Bikorimana et al., 2022). This evidence concerns the gene MCAM and graft versus host disease.